Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$206.05M
EBITDA Margin
-646.93%
TTM Avg
-391.16%
3Y Avg
-256.59%
5Y Avg
-321.84%
Market Cap
$203.92M
EBITDA Margin
-2994.14%
TTM Avg
-1551.99%
3Y Avg
-854.53%
5Y Avg
-625.57%
Market Cap
$208.37M
EBITDA Margin
-611.99%
TTM Avg
-293.95%
3Y Avg
-196.05%
5Y Avg
-196.05%
Market Cap
$202.26M
EBITDA Margin
-1195.14%
TTM Avg
-710.65%
3Y Avg
-586.79%
5Y Avg
-586.79%
Market Cap
$211.33M
EBITDA Margin
43.70%
TTM Avg
-4.00%
3Y Avg
-127.66%
5Y Avg
-437.76%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $206.19M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $206.05M | -646.93% | -391.16% | -256.59% | -321.84% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.82M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $203.92M | -2994.14% | -1551.99% | -854.53% | -625.57% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.37M | -611.99% | -293.95% | -196.05% | -196.05% |
| Pro-Dex, Inc. (PDEX)vs › | $208.71M | 18.55% | 18.23% | 16.57% | 15.69% |
| Surrozen, Inc. (SRZN)vs › | $202.26M | -1195.14% | -710.65% | -586.79% | -586.79% |
| Exagen Inc. (XGN)vs › | $200.00M | -17.95% | -19.68% | -44.09% | -43.18% |
| Compugen Ltd. (CGEN)vs › | $211.33M | 43.70% | -4.00% | -127.66% | -437.76% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.79M | -847.24% | -1408.92% | -1408.92% | -1408.92% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
